- Home
- ANNX vs MLP Comparison
ANNX vs MLP Comparison
Compare ANNX & MLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- MLP
- Stock Information
- Founded
- ANNX 2011
- MLP 1909
- Country
- ANNX United States
- MLP United States
- Employees
- ANNX N/A
- MLP N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- MLP Real Estate
- Sector
- ANNX Health Care
- MLP Finance
- Exchange
- ANNX Nasdaq
- MLP Nasdaq
- Market Cap
- ANNX 362.4M
- MLP 312.9M
- IPO Year
- ANNX 2020
- MLP 1972
- Fundamental
- Price
- ANNX $1.46
- MLP $15.00
- Analyst Decision
- ANNX Strong Buy
- MLP
- Analyst Count
- ANNX 5
- MLP 0
- Target Price
- ANNX $18.67
- MLP N/A
- AVG Volume (30 Days)
- ANNX 2.2M
- MLP 20.4K
- Earning Date
- ANNX 05-12-2025
- MLP 05-12-2025
- Dividend Yield
- ANNX N/A
- MLP N/A
- EPS Growth
- ANNX N/A
- MLP N/A
- EPS
- ANNX N/A
- MLP N/A
- Revenue
- ANNX N/A
- MLP $11,565,000.00
- Revenue This Year
- ANNX N/A
- MLP N/A
- Revenue Next Year
- ANNX N/A
- MLP N/A
- P/E Ratio
- ANNX N/A
- MLP N/A
- Revenue Growth
- ANNX N/A
- MLP 24.50
- 52 Week Low
- ANNX $1.29
- MLP $15.00
- 52 Week High
- ANNX $7.85
- MLP $26.46
- Technical
- Relative Strength Index (RSI)
- ANNX 30.77
- MLP 29.88
- Support Level
- ANNX $1.40
- MLP $14.37
- Resistance Level
- ANNX $1.68
- MLP $16.25
- Average True Range (ATR)
- ANNX 0.18
- MLP 0.90
- MACD
- ANNX 0.00
- MLP -0.12
- Stochastic Oscillator
- ANNX 19.13
- MLP 16.94
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales: , which includes land planning and entitlement, development, and sales activities.; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.